home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0114.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
2KB
|
28 lines
Document 0114
DOCN M94A0114
TI Treatment of oral Candida mucositis infections.
DT 9412
AU Garber GE; Division of Infectious Diseases, Ottawa General Hospital,;
University of Ottawa, Ontario, Canada.
SO Drugs. 1994 May;47(5):734-40. Unique Identifier : AIDSLINE MED/94349844
AB Infections due to Candida spp. are increasing in incidence as the number
of immune compromised patients increases. The common presentation of
Candida mucositis and oral infections includes atrophic candidiasis,
angular cheilitis, leukoplakia and oesophagitis. An increasing spectrum
of antifungal agents, including imidazoles, are available for treatment
and suppression of this common infection. In chronically
immune-compromised patients such as those with severe HIV related immune
deficiency, eradication of the infection may not be possible. This
requires a stepwise approach to management and may require the use of
potent, toxic agents such as amphotericin B to suppress the symptoms and
signs of infection sufficiently to provide the patient with symptomatic
relief. Resistant organisms are also becoming a greater problem in this
patient population.
DE Adult Candidiasis, Oral/*DRUG THERAPY Case Report Human Male Mouth
Mucosa/DRUG EFFECTS Risk Factors Stomatitis/DRUG THERAPY JOURNAL
ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).